Reuters logo
BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer
June 20, 2017 / 12:59 PM / 3 months ago

BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer

June 20 (Reuters) - Merck Kgaa

* Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer

* Effector Therapeutics - cos plan to initiate Phase 2 study to evaluate EFT508 in combination with avelumab in microsatellite stable relapsed or refractory CRC patients

* Effector Therapeutics - Pfizer and Merck KGAA will share clinical study costs with effector Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below